# Hinge Health, Inc.: financial statements, quarterly

HNGE · NYSE · CIK 1673743 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hnge.md) · [Financials](/companies/hnge/financials.md) · [Filings](/companies/hnge/filings.md) · [Insiders](/companies/hnge/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hnge/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [89.8](/filings/0000950170-25-106577.md) | [101](/filings/0001193125-25-272353.md) | [117 d](/filings/0001628280-26-013808.md) | [124](/filings/0001628280-26-032224.md) | [139](/filings/0001628280-26-054327.md) | [154](/filings/0001193125-25-272353.md) | [171 d](/filings/0001628280-26-013808.md) | [182](/filings/0001628280-26-032224.md) | [213](/filings/0001628280-26-054327.md) |
| Cost of revenue | $m | not reported | [23.2](/filings/0000950170-25-106577.md) | [21.4](/filings/0001193125-25-272353.md) | [21.2 d](/filings/0001628280-26-013808.md) | [23.6](/filings/0001628280-26-032224.md) | [41.3](/filings/0001628280-26-054327.md) | [28.0](/filings/0001193125-25-272353.md) | [26.7 d](/filings/0001628280-26-013808.md) | [28.1](/filings/0001628280-26-032224.md) | [28.9](/filings/0001628280-26-054327.md) |
| Gross profit | $m | not reported | [66.6](/filings/0000950170-25-106577.md) | [79.3](/filings/0001193125-25-272353.md) | [96.1 d](/filings/0001628280-26-013808.md) | [100](/filings/0001628280-26-032224.md) | [97.8](/filings/0001628280-26-054327.md) | [126](/filings/0001193125-25-272353.md) | [144 d](/filings/0001628280-26-013808.md) | [154](/filings/0001628280-26-032224.md) | [184](/filings/0001628280-26-054327.md) |
| Research and development | $m | not reported | [24.9](/filings/0000950170-25-106577.md) | [23.8](/filings/0001193125-25-272353.md) | [22.4 d](/filings/0001628280-26-013808.md) | [23.5](/filings/0001628280-26-032224.md) | [280](/filings/0001628280-26-054327.md) | [31.9](/filings/0001193125-25-272353.md) | [32.8 d](/filings/0001628280-26-013808.md) | [30.3](/filings/0001628280-26-032224.md) | [34.1](/filings/0001628280-26-054327.md) |
| Operating income | $m | not reported | [(17.6)](/filings/0000950170-25-106577.md) | [(3.8)](/filings/0001193125-25-272353.md) | [20.9 d](/filings/0001628280-26-013808.md) | [13.1](/filings/0001628280-26-032224.md) | [(581)](/filings/0001628280-26-054327.md) | [(6.1)](/filings/0001193125-25-272353.md) | [27.3 d](/filings/0001628280-26-013808.md) | [32.1](/filings/0001628280-26-032224.md) | [40.4](/filings/0001628280-26-054327.md) |
| Income tax | $m | not reported | [0.4](/filings/0000950170-25-106577.md) | [1.1](/filings/0001193125-25-272353.md) | [(1.0) d](/filings/0001628280-26-013808.md) | [1.0](/filings/0001628280-26-032224.md) | [(0.3)](/filings/0001628280-26-054327.md) | [0.2](/filings/0001193125-25-272353.md) | [0.1 d](/filings/0001628280-26-013808.md) | [0.8](/filings/0001628280-26-032224.md) | [0.7](/filings/0001628280-26-054327.md) |
| Net income | $m | [(26.5)](/filings/0001193125-25-272353.md) | [(12.9)](/filings/0001193125-25-272353.md) | [0.3](/filings/0001193125-25-272353.md) | [27.1 d](/filings/0001628280-26-013808.md) | [17.1](/filings/0001628280-26-032224.md) | [(576)](/filings/0001628280-26-054327.md) | [(1.8)](/filings/0001193125-25-272353.md) | [32.1 d](/filings/0001628280-26-013808.md) | [35.1](/filings/0001628280-26-032224.md) | [43.7](/filings/0001628280-26-054327.md) |
| Diluted EPS | $ per share | not reported | [(0.96)](/filings/0000950170-25-106577.md) | [0.01](/filings/0001193125-25-272353.md) | not reported | [1.31](/filings/0001628280-26-032224.md) | [(13.10)](/filings/0001628280-26-054327.md) | [(0.02)](/filings/0001193125-25-272353.md) | not reported | [0.41](/filings/0001628280-26-032224.md) | [0.52](/filings/0001628280-26-054327.md) |
| Basic EPS | $ per share | not reported | [(0.96)](/filings/0000950170-25-106577.md) | [0.01](/filings/0001193125-25-272353.md) | not reported | [7.91](/filings/0001628280-26-032224.md) | [(13.10)](/filings/0001628280-26-054327.md) | [(0.02)](/filings/0001193125-25-272353.md) | not reported | [0.43](/filings/0001628280-26-032224.md) | [0.55](/filings/0001628280-26-054327.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [235](/filings/0001628280-26-013808.md) | not reported | [237](/filings/0000950170-25-106577.md) | [268](/filings/0001193125-25-272353.md) | [301](/filings/0001628280-26-013808.md) | [288](/filings/0001628280-26-032224.md) | [237](/filings/0001628280-26-054327.md) | [261](/filings/0001193125-25-272353.md) | [208](/filings/0001628280-26-054327.md) | [187](/filings/0001628280-26-032224.md) | [286](/filings/0001628280-26-054327.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [583](/filings/0001628280-26-013808.md) | not reported | [598](/filings/0000950170-25-106577.md) | [659](/filings/0001193125-25-272353.md) | [534](/filings/0001628280-26-054327.md) | [540](/filings/0001628280-26-032224.md) | [643](/filings/0001628280-26-054327.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | not reported | [673](/filings/0001628280-26-013808.md) | not reported | [694](/filings/0000950170-25-106577.md) | [770](/filings/0001193125-25-272353.md) | [745](/filings/0001628280-26-054327.md) | [729](/filings/0001628280-26-032224.md) | [827](/filings/0001628280-26-054327.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [249](/filings/0001628280-26-013808.md) | not reported | [314](/filings/0000950170-25-106577.md) | [357](/filings/0001193125-25-272353.md) | [362](/filings/0001628280-26-054327.md) | [414](/filings/0001628280-26-032224.md) | [481](/filings/0001628280-26-054327.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [257](/filings/0001628280-26-013808.md) | not reported | [320](/filings/0000950170-25-106577.md) | [362](/filings/0001193125-25-272353.md) | [366](/filings/0001628280-26-054327.md) | [417](/filings/0001628280-26-032224.md) | [483](/filings/0001628280-26-054327.md) |
| Shareholders' equity | $m | [(318)](/filings/0001628280-26-013808.md) | [(424)](/filings/0001628280-26-013808.md) | [(450)](/filings/0001193125-25-272353.md) | [(463)](/filings/0001193125-25-272353.md) | [(462)](/filings/0001193125-25-272353.md) | [(435)](/filings/0001628280-26-054327.md) | [(308)](/filings/0001628280-26-054327.md) | [174](/filings/0001628280-26-054327.md) | [208](/filings/0001193125-25-272353.md) | [179](/filings/0001628280-26-054327.md) | [112](/filings/0001628280-26-054327.md) | [344](/filings/0001628280-26-054327.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [28.4 d](/filings/0001193125-25-272353.md) | [38.3 d](/filings/0001628280-26-013808.md) | [4.9](/filings/0001628280-26-032224.md) | [20.2 d](/filings/0001628280-26-054327.md) | [82.4 d](/filings/0001193125-25-272353.md) | [63.9 d](/filings/0001628280-26-013808.md) | [43.1](/filings/0001628280-26-032224.md) | [101 d](/filings/0001628280-26-054327.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001193125-25-272353.md) | [0.2 d](/filings/0001628280-26-013808.md) | [0.1](/filings/0001628280-26-032224.md) | [0.2 d](/filings/0001628280-26-054327.md) | [0.1 d](/filings/0001193125-25-272353.md) | [0.4 d](/filings/0001628280-26-013808.md) | [0.1](/filings/0001628280-26-032224.md) | [0.1 d](/filings/0001628280-26-054327.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001628280-26-032224.md) | [0.0 d](/filings/0001628280-26-054327.md) | not reported | not reported | [105](/filings/0001628280-26-032224.md) | [26.5 d](/filings/0001628280-26-054327.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.5](/filings/0000950170-25-106577.md) | [16.6](/filings/0001193125-25-272353.md) | [92.7](/filings/0001628280-26-032224.md) | [43.9](/filings/0001628280-26-054327.md) | [78.9](/filings/0001193125-25-272353.md) | [82.4](/filings/0001628280-26-032224.md) | [83.4](/filings/0001628280-26-054327.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.